Celerion
Neptune, New Jersey, United States
Research foundation in Neptune Township, New Jersey
1930 Heck Ave, Neptune City, NJ 07753
About Celerion
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Celerion
During the past decade, Celerion conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
1995-02-01
Completed
3,300
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
2001-06-01
2009-12-01
Completed
3,010
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
2002-08-01
2013-06-01
Completed
1,512
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
2003-09-01
2021-05-31
Completed
2,980
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
2003-11-01
Unknown status
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
2005-05-01
Completed
700
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
2006-05-01
Completed
3,400
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
2008-02-01
2014-09-01
Completed
820
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Celerion" #1 sponsor was "AEterna Zentaris" with 1 trials, followed by "AstraZeneca" with 1 trials
sponsored, "GliaCure, Inc." with 1 trials sponsored, "Mannkind Corporation" with 1 trials sponsored and "Optinose US Inc."
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
Clinical Trials Conditions at Celerion
According to Clinical.Site data, the most researched conditions in "Celerion" are
"Healthy Volunteers" (2 trials), "Diagnosis of Adult Growth Hormone Deficiency (AGDH)" (1 trials), "Hypertriglyceridemia" (1 trials) and "Migraine" (1 trials). Many other conditions were trialed in "Celerion" in a lesser frequency.
Clinical Trials Intervention Types at Celerion
Most popular intervention types in "Celerion" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "AEZS-130 (formerly ARD-07)" (1 trials), "Epanova™ QD (2 x 1 g capsules)" (1 trials), "GC021109" (1 trials), "L-ARG+GHRH" (1 trials) and "Multiple (20) oral doses of 2 g Vascepa® every 12 hours" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Celerion
The vast majority of trials in "Celerion" are
5 trials for "All" genders.
Clinical Trials Status at Celerion
Currently, there are NaN active trials in "Celerion".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in Celerion,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Celerion, 4 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".